CytomX Therapeutics Presents Overview of

– Presentation at World ADC Conference in San Diego –

– CX-2051 integrates CytomX core platform experience to probably maximize therapeutic window –

SOUTH SAN FRANCISCO, Calif., Sept. 07, 2022 (GLOBE NEWSWIRE) — CytomX Therapeutics, Inc. (Nasdaq: CTMX), a frontrunner within the discipline of conditionally activated oncology therapeutics, immediately introduced that the Company offered advances inside its conditionally-activated ADC portfolio, together with the following technology EpCAM-ADC, CX-2051, on the World ADC convention happening September 6-9, 2022, in San Diego, CA.

“The momentum in the field of ADC therapeutics is incredibly exciting and holds great promise for the innovation and development of novel oncology therapeutics. Our pioneering work and experience in applying our versatile Probody^® platform to the ADC modality has the potential to expand the universe of addressable targets and to further increase the therapeutic window of future molecules entering the clinic,” mentioned Marcia P. Belvin, Ph.D., senior vp and head of analysis at CytomX. “CX-2051, our EpCAM-targeted, conditionally activated ADC, is strategically tailored to optimize the therapeutic index for systemic treatment of EpCAM-expressing epithelial cancers, which is an area of high unmet need where, to date, efforts have not been successful due to dose-limiting toxicities.”

“Our strategy with CX-2051 is to match payload mechanism of action with tumor sensitivity, and we have selected the topoisomerase-1 inhibitor, camptothecin, as the payload for our newest ADC,” Dr. Belvin continued. “Topoisomerase-1 inhibitor-conjugated ADCs are showing impressive clinical activity, and importantly, the safety profiles of camptothecin and its derivatives have been well characterized. Additionally, two camptothecin derivatives, irinotecan and topotecan, have been approved by the U.S. Food and Drug Administration for clinical use – irinotecan for pancreatic and colorectal cancer, and topotecan for ovarian, cervical, and small cell lung cancer. We plan to pursue multiple indications with this new therapeutic candidate and look forward to progressing to an investigational new drug application submission in the second half of 2023.”

Presentation highlights embody:

• Review of scientific exercise for the conditionally activated ADCs CX-2029 and praluzatamab ravtansine (CX-2009), concentrating on CD71 and CD166, respectively. CD71 and CD166 have traditionally been inaccessible targets for conventional ADCs because of their excessive expression ranges on regular tissues. The knowledge offered exhibit scientific anti-cancer exercise and a therapeutic window for these beforehand undruggable targets.
• The molecular construction of CX-2051, a masked, conditionally activated, EpCAM-targeting ADC with a subsequent technology camptothecin-based linker payload. CX-2051 highlights the potential for CytomX’s Probody know-how to unlock a brand new ADC goal (EpCAM/Trop-1), which is a goal that has beforehand yielded promising scientific outcomes solely by domestically administered therapies.
• CX-2051 preclinical knowledge indicating robust anti-cancer exercise and tolerability with a good predicted therapeutic index.

The full presentation is offered on the following hyperlink:

Tailoring the Selection of Target, Payload, & Tumor Type to Maximize the Therapeutic Index of Conditionally Activated ADCs
Marcia P. Belvin, Ph.D., Senior Vice President, Head of Research, CytomX Therapeutics
Presentation Link

About CytomX Therapeutics, Inc.
CytomX is a clinical-stage, oncology-focused biopharmaceutical firm devoted to destroying most cancers in a different way. By pioneering a novel class of conditionally activated biologics, powered by its Probody® know-how platform, CytomX’s aim is to transcend the boundaries of present most cancers therapies. CytomX’s sturdy and differentiated pipeline includes seven therapeutic candidates throughout a number of remedy modalities. Three of these candidates are in Phase 2 research throughout a number of most cancers varieties, together with CX-2029 and praluzatamab ravtansine. CX-2029 is an investigational conditionally activated antibody-drug conjugate (ADC) directed towards CD71, which has demonstrated encouraging antitumor exercise in sufferers with squamous non-small cell lung most cancers and is being developed in collaboration with AbbVie. Praluzatamab ravtansine is an investigational conditionally activated ADC directed towards CD166 and is being studied in sufferers with superior breast most cancers. CytomX’s scientific pipeline additionally contains most cancers immunotherapeutic candidates in opposition to validated targets such because the CTLA-4-targeting Probody therapeutics, BMS-986249 and BMS-986288, partnered with Bristol Myers Squibb, in addition to CX-904, a conditionally activated T-cell-engaging bispecific antibody concentrating on the epidermal progress issue receptor on tumor cells and the CD3 receptor on T cells, which is partnered with Amgen. In addition, CytomX has a various preclinical portfolio of wholly-owned belongings similar to CX-801, an interferon alpha-2b Probody cytokine that has broad potential applicability in historically immuno-oncology delicate in addition to insensitive (chilly) tumors and CX-2051, a conditionally activated ADC directed towards EpCAM, with potential applicability throughout a number of EpCAM-expressing epithelial cancers. CytomX has established strategic collaborations with a number of leaders in oncology, together with AbbVie, Amgen, Astellas, and Bristol Myers Squibb. For extra details about CytomX and the way it’s working to make conditionally activated therapies the brand new standard-of-care within the battle in opposition to most cancers, go to www.cytomx.com and comply with us on LinkedIn and Twitter.

Forward-Looking Statements
This press launch contains forward-looking statements. Such forward-looking statements contain identified and unknown dangers, uncertainties and different necessary components which can be troublesome to foretell, could also be past our management, and will trigger the precise outcomes, efficiency or achievements to be materially totally different from any future outcomes, efficiency or achievements expressed or implied in such statements, together with these associated to the potential of Antibody Drug Conjugates, Probody Drug Conjugates or CX-2051. Accordingly, you shouldn’t depend on any of these forward-looking statements, together with these regarding the potential advantages, security and efficacy or progress of CytomX’s or any of its collaborative companions’ product candidates, together with praluzatamab ravtansine, CX-2029, BMS-986249, BMS-986288, pacmilimab, CX-904, CX-801, and CX-2051, the potential advantages or purposes of CytomX’s Probody platform know-how, CytomX’s skill to develop and advance product candidates into and efficiently full scientific trials, together with the continued and deliberate scientific trials of praluzatamab ravtansine, CX-2029, BMS-986249, BMS-986288, pacmilimab, and CX-904, and the timing of the graduation of scientific trials, preliminary and ongoing knowledge availability, investigational new drug purposes and different growth milestones. Risks and uncertainties that contribute to the unsure nature of the forward-looking statements embody: the unproven nature of CytomX’s novel Probody Platform know-how; CytomX’s scientific trial product candidates are within the preliminary levels of scientific growth and its different product candidates are presently in preclinical growth, and the method by which preclinical and scientific growth may probably result in an permitted product is lengthy and topic to important dangers and uncertainties, together with the danger that the COVID-19 worldwide pandemic could proceed to negatively affect the business, analysis and scientific operations of CytomX or its companions, together with the event of preclinical drug candidates because of delays in and disruption of analysis actions and the event of scientific drug candidates because of delays in or disruption of scientific trials, together with impacts on the enrollment of sufferers in scientific trials or different scientific trial disruptions; the chance that the outcomes of preclinical analysis and early scientific trials will not be predictive of future outcomes; the chance that CytomX’s scientific trials won’t achieve success; the chance that present preclinical analysis could not lead to further product candidates; CytomX’s dependence on the success of praluzatamab ravtansine, CX-2029, BMS-986249, BMS-986288, pacmilimab, CX-904, CX-801, and CX-2051; CytomX’s reliance on third events for the manufacture of the Company’s product candidates; and potential regulatory developments in the United States and overseas international locations. Additional relevant dangers and uncertainties embody these regarding our preclinical analysis and growth, scientific growth, and different dangers recognized beneath the heading “Risk Factors” included in CytomX’s Quarterly Report on Form 10-Q filed with the SEC on August 4, 2022. The forward-looking statements contained on this press launch are primarily based on data presently obtainable to CytomX and communicate solely as of the date on which they’re made. CytomX doesn’t undertake and particularly disclaims any obligation to replace any forward-looking statements, whether or not in consequence of any new data, future occasions, modified circumstances or in any other case.

Probody is a U.S. registered trademark of CytomX Therapeutics, Inc.

CytomX Contact:
Chris Ogden
Senior Vice President, Head of Finance
[email protected]
(317) 767-4764

Investor and Media Contact:
Stern Investor Relations
Stephanie Ascher
[email protected]
(212) 362-1200